December 26, 2025 01:24 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Tarique Rahman returns to Bangladesh after 17 years | Shocking killing inside AMU campus: teacher shot dead during evening walk | Horror on Karnataka highway: sleeper bus bursts into flames after truck crash, 9 killed | PM Modi attends Christmas service at Delhi church, sends message of love and compassion | Delhi erupts over lynching of Hindu man in Bangladesh; protest outside High Commission | Targeted killing sparks global outrage: American lawmakers condemn mob lynching of Hindu man in Bangladesh | Assam on a ‘powder keg’: Himanta Biswa Sarma flags demographic shift, Chicken’s Neck fears | Bangladesh on edge: Student leader shot as pre-poll violence deepens after Hadi killing | Historic deal sealed: India, New Zealand sign landmark Free Trade Agreement in record time | Supreme court snubs urgent plea to stop PMO’s chadar offering at Ajmer Sharif
UK | COVID booster vaccine

UK approves COVID-19 booster vaccine for people over 40 years

| @indiablooms | Nov 16, 2021, at 01:32 am

London/UNI/Sputnik: The United Kingdom’s Joint Committee on Vaccination and Immunisation (JCVI) on Monday announced that people over 40 years old living in the country will now be eligible to receive a booster COVID-19 vaccine six months after having their second dose, as a new study showed that boosters give over 90 percent protection in adults over 50.

“JCVI has previously advised booster vaccination for all adults aged 50 years and over and those in a Covid-19 at-risk group. The offer has now been broadened to include those aged 40 to 49 years,” the committee said in a statement.

The booster vaccines to be offered to this new age group are Pfizer-BioNTech and Moderna, the same mRNA-type vaccine that has been used since September in people over 50 and at higher risk from the coronavirus SARS-CoV-2.

So far, more than 12,6 million people in the UK have had the third dose.

According to a study released on Monday by the UK Health Security Agency, two weeks after receiving a booster dose, protection against symptomatic infection in adults aged 50 years and over was 93.1 percent in those who first had AstraZeneca as their primary vaccine and 94.0 percent for Pfizer-BioNTech.

The JCVI also advised that all 16- to 17-year-olds who are not in an at-risk group should be offered a second dose of the Pfizer vaccine 12 weeks or more following the first vaccine dose.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.